Data as of 3:59pm ET
| +0.36 / +5.72%|
The 3 analysts offering 12-month price forecasts for Cancer Genetics Inc have a median target of 15.75, with a high estimate of 20.00 and a low estimate of 13.00. The median estimate represents a +136.84% increase from the last price of 6.65.
The current consensus among 3 polled investment analysts is to Buy stock in Cancer Genetics Inc. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.